FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease

被引:0
|
作者
Bernstein, Elana J. [1 ]
Boin, Francesco [2 ]
Elicker, Brett [3 ]
Luo, Yiming [1 ]
Ren, Yawen [4 ]
Zhang, Meng [5 ]
Varga, John [6 ]
Assassi, Shervin [5 ]
机构
[1] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Dept Med,Div Rheumatol, New York, NY USA
[2] Cedars Sinai Med Ctr, Dept Med, Div Rheumatol, Los Angeles, CA USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[4] Univ Colorado, Dept Med, Div Rheumatol, Denver, CO USA
[5] Univ Texas Hlth Sci Ctr Houston, UTHlth Houston, Dept Med, Div Rheumatol, Houston, TX USA
[6] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
systemic sclerosis; interstitial lung disease; usual interstitial pneumonia; FAM13A; MUC5B; IDIOPATHIC PULMONARY-FIBROSIS; PROMOTER POLYMORPHISM; SUSCEPTIBILITY; GENE; SCLERODERMA; LOCI;
D O I
10.1093/rheumatology/keae573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The MUC58 promoter single nucleotide polymorphism (SNP) rs35705950 has been associated with idiopathic pulmonary fibrosis (IPF) and RA-related interstitial lung disease (ILD), but not with SSc-ILD. We hypothesized that the MUC58 promoter polymorphism or other IPF susceptibility loci are associated with an increased risk for the uncommon SSc-usual interstitial pneumonia (UIP) endophenotype, rather than SSc-ILD in general. Methods: We performed a cross-sectional study of SSc-ILD patients from four US Scleroderma Programs to investigate the frequency of MUC58 rs35705950 and 12 additional IPF susceptibility loci. SSc-ILD patients were stratified by high resolution chest CT (HRCT) imaging findings into UIP and non-UIP groups. Analysis of HRCTs performed by a thoracic radiologist blinded to participants' characteristics classified each scan as definite UIP, probable UIP, indeterminate or alternative diagnosis, according to American Thoracic Society criteria. Results: Four-hundred and eighty-nine SSc-ILD patients were included; 80% were female and 75% were White. Twenty-three (4.7%) patients had a definite UIP pattern. The MUC58 SNP rs35705950 was not associated with a definite UIP pattern in SSc-ILD. In contrast, patients carrying two copies of the IPF risk gene FAM13A minor allele rs2609255 had significantly higher odds of a definite UIP pattern compared with the other patterns (odds ratio 3.40, 95% CI 1.19-9.70), and compared with an alternative diagnosis (odds ratio 3.65, 95% CI 1.25-10.65). Conclusion: We demonstrated a novel association between FAM13A and SSc-UIP. Contrary to IPF and RA-ILD, the MUC58 promoter polymorphism was not associated with a definite UIP pattern in SSc-ILD.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis-associated interstitial lung disease
    Kuzumi, Ai
    Mitsuo, Shunki
    Miyake, Tomomi
    Sato, Shinichi
    Yoshizaki, Ayumi
    RHEUMATOLOGY, 2023, 62 : SI143 - SI144
  • [32] Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
    Rahaghi, Franck F.
    Hsu, Vivien M.
    Kaner, Robert J.
    Mayes, Maureen D.
    Rosas, Ivan O.
    Saggar, Rajan
    Steen, Virginia D.
    Strek, Mary E.
    Bernstein, Elana J.
    Bhatt, Nitin
    Castelino, Flavia V.
    Chung, Lorinda
    Domsic, Robyn T.
    Flaherty, Kevin R.
    Gupta, Nishant
    Kahaleh, Bashar
    Martinez, Fernando J.
    Morrow, Lee E.
    Moua, Teng
    Patel, Nina
    Shlobin, Oksana A.
    Southern, Brian D.
    Volkmann, Elizabeth R.
    Khanna, Dinesh
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [33] Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
    C. Meier
    K. Freiburghaus
    C. Bovet
    J. Schniering
    Y. Allanore
    O. Distler
    C. Nakas
    B. Maurer
    Scientific Reports, 10
  • [34] evaluation of esophageal involvement in systemic sclerosis-associated interstitial lung disease
    Abida, Houssem
    Meddeb, Zeineb
    Abdelkefi, Cherifa
    El Ouni, Amira
    Toujani, Sana
    Hamzaoui, Saloua B'chir
    Larbi, Thara
    Bouslama, Kamel
    ACTA CLINICA BELGICA, 2023, 78 : 19 - 19
  • [35] Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
    Meier, C.
    Freiburghaus, K.
    Bovet, C.
    Schniering, J.
    Allanore, Y.
    Distler, O.
    Nakas, C.
    Maurer, B.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [36] The hidden costs of living with systemic sclerosis-associated interstitial lung disease
    Parfrey, Helen
    RESPIROLOGY, 2022, 27 (07) : 486 - 487
  • [37] Characterization of the Pericyte Transcriptome in Systemic Sclerosis-associated Interstitial Lung Disease
    Wilson, C. L.
    Renaud, L.
    Simon, B.
    Feghali-Bostwick, C.
    Schnapp, L. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [38] Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
    Franck F. Rahaghi
    Vivien M. Hsu
    Robert J. Kaner
    Maureen D. Mayes
    Ivan O. Rosas
    Rajan Saggar
    Virginia D. Steen
    Mary E. Strek
    Elana J. Bernstein
    Nitin Bhatt
    Flavia V. Castelino
    Lorinda Chung
    Robyn T. Domsic
    Kevin R. Flaherty
    Nishant Gupta
    Bashar Kahaleh
    Fernando J. Martinez
    Lee E. Morrow
    Teng Moua
    Nina Patel
    Oksana A. Shlobin
    Brian D. Southern
    Elizabeth R. Volkmann
    Dinesh Khanna
    Respiratory Research, 24
  • [39] Consensus statements for managing systemic sclerosis-associated interstitial lung disease
    Proudman, Susanna
    LANCET RHEUMATOLOGY, 2020, 2 (02): : E64 - E65
  • [40] Severity and features of frailty in systemic sclerosis-associated interstitial lung disease
    Guler, Sabina A.
    Kwan, Joanne M.
    Winstone, Tiffany A.
    Milne, Kathryn M.
    Dunne, James V.
    Wilcox, Pearce G.
    Ryerson, Christopher J.
    RESPIRATORY MEDICINE, 2017, 129 : 1 - 7